{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-002799","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.908887+00:00","generated_at":"2026-05-15T02:37:24.481804+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Anika Q1 revenue up 13% to $29.6M; adjusted EBITDA improves to $4.3M; directors resign","bullets":["Total revenue $29.6M (+13% YoY); Commercial Channel +12%, OEM +14%.","Gross margin 64.2% vs 56.1% YoY on operational execution and favorable mix.","GAAP loss from continuing ops $5.1M ($0.37 diluted); adjusted net income $3.8M ($0.27 diluted).","Adjusted EBITDA $4.3M vs $0.1M prior year; FY2026 guidance reaffirmed (revenue $114-122.5M).","Board members Jellison and Larsen resign effective 2026 annual meeting; share repurchase $15M completed at avg $10.76/share."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-002799","json":"https://secwatch.observer/filing/0001171843-26-002799.json","markdown":"https://secwatch.observer/filing/0001171843-26-002799.md","text":"https://secwatch.observer/filing/0001171843-26-002799.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184326002799/0001171843-26-002799-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184326002799/f8k_042926.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T02:37:24.481804+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"37a708e2e24df3acbe979c6b508df07fa44127c8","claim":"Anika Therapeutics, Inc. reported first quarter 2026 results: revenue $29.6 million, net income $5.1 million loss, EPS ($0.37) per diluted share.","evidence_excerpt":"First Quarter 2026 Continuing Operations Financial Summary Revenue $29.6 million, up 13% year over year Commercial Channel revenue $12.6 million, up 12% OEM Channel revenue $17.0 million, up 14% Gross margin 64.2% Operating expenses $24.5 million, including $4.9 million of one-time severance expenses GAAP loss from continuing operations $5.1 million, ($0.37) per diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184326002799/0001171843-26-002799-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2026"},{"label":"Revenue","value":"$29.6 million"},{"label":"Net income","value":"$5.1 million loss"},{"label":"EPS","value":"($0.37) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"8de475fcfb8cd98c9834db5b76d63b755d345f3b","claim":"Anika Therapeutics, Inc. reported fiscal year 2026 results: revenue $114 to $122.5 million. Guidance reaffirmed.","evidence_excerpt":"Fiscal 2026 Guidance Anika is maintaining the previously provided 2026 guidance: Total Company Revenue between $114 and $122.5 million, up 1% to 9% year over year Commercial Channel, $53 to $58 million, representing growth of 10% to 20% year over year OEM Channel, $61 to $64.5 million, flat to modestly lower year over year Adjusted EBITDA as a percent of revenue between 5% and 10%, reflecting higher revenues and reduced expenses offset by modestly lower U.S. pricing dynamics.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184326002799/0001171843-26-002799-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2026"},{"label":"Revenue","value":"$114 to $122.5 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"2b475e0d08","claim":"William R. Jellison resigned as Class I member of the Board of Directors at Anika Therapeutics, Inc..","evidence_excerpt":"On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the \"Board\") of the Company, and Glenn R. Larsen, Ph.D., a Class II member of the Board, notified the Board of their resignation from the Board, including from all committees on which each serves effective as of the Company's 2026 annual meeting of stockholders (the \"2026 Annual Meeting\").","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184326002799/0001171843-26-002799-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Class I member of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"66d9944cf4","claim":"Glenn R. Larsen resigned as Class II member of the Board at Anika Therapeutics, Inc..","evidence_excerpt":"On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the \"Board\") of the Company, and Glenn R. Larsen, Ph.D., a Class II member of the Board, notified the Board of their resignation from the Board, including from all committees on which each serves effective as of the Company's 2026 annual meeting of stockholders (the \"2026 Annual Meeting\").","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184326002799/0001171843-26-002799-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Class II member of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}